ANGLE plc announced that Garth Selvey has informed the Board of his intention to retire and leave ANGLE at the publication of the 2023 Interims in September. Garth will hand over the Chair with immediate effect to Dr. Jan Groen, currently an independent Non-executive Director on the Board. Garth joined ANGLE as a Non-executive Director in 2006 and became Chairman in 2007.

Under his guidance, ANGLE has made significant progress in the development of its ground-breaking Parsortix® liquid biopsy system from its early adoption by leading cancer centers for oncology research through to its FDA clearance for use in metastatic breast cancer in May last year. Dr. Jan Groen has over twenty years of experience in medical diagnostics covering both pharma and clinical sales, which provides critical market insight as ANGLE drives forward its commercial product roll-out and the expansion of its clinical laboratories and CTC services. Jan joined the ANGLE Board as a Non-executive Director in November 2018.

Jan is currently the CEO and Chairman at Intravacc B.V. and was previously the CEO of MDxHealth, a Euronext listed genomic diagnostics company specializing in prostate cancer, and President and COO of Agendia, a company specializing in breast cancer. Jan's appointment as Chairman follows the new Non-executive Director appointments of Juliet Thompson and Dr. Joseph Eid earlier this year.